Chiasma, Inc. (CHMA) Lifted to “Sell” at ValuEngine
ValuEngine upgraded shares of Chiasma, Inc. (NASDAQ:CHMA) from a strong sell rating to a sell rating in a research report sent to investors on Friday.
Shares of Chiasma (NASDAQ:CHMA) traded up 4.55% during mid-day trading on Friday, reaching $2.30. The company had a trading volume of 126,739 shares. Chiasma has a 52 week low of $1.25 and a 52 week high of $3.71. The company’s market capitalization is $56.03 million. The stock has a 50 day moving average of $1.68 and a 200-day moving average of $1.59.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related stocks with our FREE daily email newsletter.